- Home
- CRVS vs NBTX Comparison
CRVS vs NBTX Comparison
Compare CRVS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- NBTX
- Stock Information
- Founded
- CRVS 2014
- NBTX 2003
- Country
- CRVS United States
- NBTX France
- Employees
- CRVS N/A
- NBTX N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- NBTX Health Care
- Exchange
- CRVS Nasdaq
- NBTX Nasdaq
- Market Cap
- CRVS 206.5M
- NBTX 167.8M
- IPO Year
- CRVS 2016
- NBTX 2020
- Fundamental
- Price
- CRVS $3.61
- NBTX $3.86
- Analyst Decision
- CRVS Strong Buy
- NBTX Strong Buy
- Analyst Count
- CRVS 3
- NBTX 1
- Target Price
- CRVS $16.33
- NBTX $8.00
- AVG Volume (30 Days)
- CRVS 1.6M
- NBTX 11.3K
- Earning Date
- CRVS 05-08-2025
- NBTX 04-02-2025
- Dividend Yield
- CRVS N/A
- NBTX N/A
- EPS Growth
- CRVS N/A
- NBTX N/A
- EPS
- CRVS N/A
- NBTX N/A
- Revenue
- CRVS N/A
- NBTX N/A
- Revenue This Year
- CRVS N/A
- NBTX N/A
- Revenue Next Year
- CRVS N/A
- NBTX $221.06
- P/E Ratio
- CRVS N/A
- NBTX N/A
- Revenue Growth
- CRVS N/A
- NBTX N/A
- 52 Week Low
- CRVS $1.75
- NBTX $2.76
- 52 Week High
- CRVS $10.00
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- CRVS 50.22
- NBTX 59.50
- Support Level
- CRVS $3.46
- NBTX $3.60
- Resistance Level
- CRVS $4.53
- NBTX $4.04
- Average True Range (ATR)
- CRVS 0.28
- NBTX 0.23
- MACD
- CRVS 0.02
- NBTX 0.06
- Stochastic Oscillator
- CRVS 32.60
- NBTX 66.48
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.